DUPLEX (2023) — Trial Summary

DUPLEX (2023): The DUPLEX phase 3 trial evaluated sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, versus irbesartan in patients with focal segmental glomerulosclerosis (FSGS).

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.